Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, with outbreaks continuing to emerge globally and domestically.
While TB rates in the U.S. are low, the disease is on the rise according to the World Health Organization’s 2024 country report for the United States and certain populations are at high risk, such as persons from countries where TB is common and those with little access to health services. Experts emphasize the importance of ongoing research and prevention. Rutgers New Jersey Medical School’s Public Health Research Institute, Emerging Pathogens Center (EPC) and the Global Tuberculosis Institute are at the forefront of TB research, prevention and treatment.
Rajita Bhavaraju, director of global operations for the RePORT International Coordinating Center at EPC, and Jerrold Ellner, director of research innovations and professor of medicine, discuss what TB is, its spread, at-risk populations and the role Rutgers Health continues to play in combating this disease. To read the full story.